Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II, 2nd Line Melanoma - RAND Monotherapy

This study has been completed.
Information provided by:
Bristol-Myers Squibb Identifier:
First received: January 30, 2008
Last updated: January 24, 2011
Last verified: January 2010

The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks

Condition Intervention Phase
Drug: Anti-CD137 (4-1BB) (BMS-663513)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate [ Time Frame: every 6 weeks starting at week 12 after randomization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety profiles [ Time Frame: throughout the study ] [ Designated as safety issue: Yes ]
  • Disease response rate [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Disease control rate [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • 1-year survival [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Pharmacokinetics [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
  • Pharmacodynamics [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
  • Biomarkers [ Time Frame: throughout the study ] [ Designated as safety issue: No ]

Enrollment: 158
Study Start Date: March 2008
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1
0.1 mg/kg every 3 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity
Active Comparator: Arm 2
1 mg/kg every 3 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity
Active Comparator: Arm 3
1 mg/kg every 6 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity
Active Comparator: Arm 4
5 mg/kg every 3 weeks
Drug: Anti-CD137 (4-1BB) (BMS-663513)
IV solution, IV, until PD or toxicity


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have been previously treated with one line of systemic anti-cancer therapy (non-experimental or experimental) for metastatic disease, and relapsed, failed to respond (CR or PR) or did not tolerate that regimen. If the treatment has been administered as an adjuvant and/or neoadjuvant therapy, the subject must have documented disease progression from the last treatment and also received one additional line of systemic therapy for metastatic disease.
  • Men and women, who are at least 18 years of age

Exclusion Criteria:

  • Ocular or mucosal melanoma
  • Complete surgical resection of all identifiable sites of disease
  • Symptomatic brain metastasis. Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by computerized axial tomography (CT) scan or magnetic resonance imaging (MRI). Subjects with stable brain metastasis and those who were previously treated with radiotherapy or surgery must have no current evidence of symptomatic brain metastasis and are off steroid therapy for at least 4 weeks prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00612664

  Show 32 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Study Director, Bristol-Myers Squibb Identifier: NCT00612664     History of Changes
Other Study ID Numbers: CA186-006
Study First Received: January 30, 2008
Last Updated: January 24, 2011
Health Authority: United States: Food and Drug Administration
Austria: Ethikkommission
Brazil: National Committee of Ethics in Research
Brazil: Ministry of Health
Canada: Ethics Review Committee
Denmark: Danish Medicines Agency
Germany: Paul-Ehrlich-Institut
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Italy: Ethics Committee

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas processed this record on November 20, 2014